| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/09/2005 | EP1392285B1 Medicament containing an effector of the glutathione metabolism together with alpha-lipoic acid for use in kidney replacement therapy |
| 02/09/2005 | EP1390031B1 Topical composition containing a fungicide |
| 02/09/2005 | EP1387683B1 Novel salt and crystalline forms of (2r)-anti-5-3-(4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl)-2-hydroxypropoxy quinoline |
| 02/09/2005 | EP1370268A4 Methods for treating stress disorders using glucocorticoid receptor-specific antagonists |
| 02/09/2005 | EP1349846B1 Arylated furane and thiophene carboxylic acid amides with potassium channel blocking effect |
| 02/09/2005 | EP1339717B1 Novel carbamate-substituted pyrazolopyridine derivatives |
| 02/09/2005 | EP1313885A4 Methods of using agents that modulate bone formation and inhibit adipogenesis |
| 02/09/2005 | EP1307209B1 Cardioplegic solution |
| 02/09/2005 | EP1274980A4 Solution and crystal structures of mmp-13 active site and uses thereof |
| 02/09/2005 | EP1255850A4 AMPLIFICATION OF $i(CYP24) AND USES THEREOF |
| 02/09/2005 | EP1244640B1 Oxazolidinone derivatives |
| 02/09/2005 | EP1200076A4 Calcilytic compounds |
| 02/09/2005 | EP1191924A4 Pharmaceutical dosage form for pulsatile delivery of (d-threo)-methylphenidate and a second cns stimulant |
| 02/09/2005 | EP1165054A4 Pharmaceutical dosage form for pulsatile delivery of methylphenidate |
| 02/09/2005 | EP1150960B1 Polymorphic crystalline forms of celecoxib |
| 02/09/2005 | EP1098639B1 Use of the glucose uptake enhancer rosiglitazone for reducing ischaemia-induced apoptosis of pancreatic beta cells, endothelial cells and neuronal cells |
| 02/09/2005 | EP1096919B1 Endoscopic transluminal delivery device comprising a pellet containing a local anesthetic agent |
| 02/09/2005 | EP1082875A4 Improved brush block housing for propeller deicing system |
| 02/09/2005 | EP1079813B1 Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces |
| 02/09/2005 | EP0941093B1 Use of nk-1 receptor antagonists for treating major depressive disorders with anxiety |
| 02/09/2005 | CN1578781A 1, 8 naphthyridine derivatives and their use to treat diabetes and related disorders |
| 02/09/2005 | CN1578780A 1, 6-naphthyridine derivatives as antidiabetics and pharmaceutical compositions containing them |
| 02/09/2005 | CN1578688A Method and apparatus for the photomodulation of living cells |
| 02/09/2005 | CN1578677A Improved therapeutic protocols |
| 02/09/2005 | CN1578675A Extended, controlled-release pharmaceutical compositions using charged polymers |
| 02/09/2005 | CN1578674A Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination |
| 02/09/2005 | CN1578665A Type 4 phosphodiesterase inhibitors and uses thereof |
| 02/09/2005 | CN1578659A Modulators of peroxisome proliferator activated receptors (ppar) |
| 02/09/2005 | CN1578657A Process for the preparation of fast dissolving dosage form |
| 02/09/2005 | CN1578650A Compositions for the treatment of infectious diseases |
| 02/09/2005 | CN1578647A Implantable and sealable system for unidirectional delivery of therapeutic agents to tissues |
| 02/09/2005 | CN1578626A Multivesicular emulsion topical delivery systems |
| 02/09/2005 | CN1576275A Substituted bicyclic derivatives for the treatment of abnormal cell growth |
| 02/09/2005 | CN1575816A Compounds for the treatment of female sexual dysfunction |
| 02/09/2005 | CN1188428C 6-mercapto-cyclodextrin derivs medical composition containing the same derivs and use thereof |
| 02/09/2005 | CN1188165C Method for treating pain by peripheral administration of neurotoxin |
| 02/09/2005 | CN1188164C Compositions and method for regulating phagocytosis and ICAM-1 expression |
| 02/09/2005 | CN1188137C Use of erythrogenin and molecule with active EPO receptor ability or analog EPO activation in pharmacy |
| 02/09/2005 | CN1188136C Buffered composition for dialysis |
| 02/09/2005 | CN1188123C Novel use of (R)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylamino methyl]-benzodihydropyran and its physiologically acceptable salts |
| 02/09/2005 | CN1188113C Pharmaceutical mixture comprising a combination of a profen and other active compounds |
| 02/09/2005 | CN1188111C Dry powder compositions having improved dispersivity |
| 02/08/2005 | US6852870 Omega-3 fatty acids in the treatment of depression |
| 02/08/2005 | US6852839 Fhm, a novel member of the TNF ligand supergene family |
| 02/08/2005 | US6852749 Pyrazolidinol compounds |
| 02/08/2005 | US6852743 Preventives for the recurrence of cerebrovascular failure and agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof |
| 02/08/2005 | US6852739 Novel nitrosated and/or nitrosylated proton pump inhibitor compounds, and novel compositions comprising at least one proton pump inhibitor compound that is optionally substituted with at least one NO and/or N02 group, and, optionally, at |
| 02/08/2005 | US6852738 Potent ligands for PPAR gamma and generally have antagonist or partial agonist activity. The compoundsare for treatment, control or prevention of obesity, non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, |
| 02/08/2005 | US6852722 Administering a growth hormone secretagogue. |
| 02/08/2005 | US6852719 Glucocorticoid receptor modulators |
| 02/08/2005 | US6852710 Antitumor agents, anticancer agents |
| 02/08/2005 | US6852708 Use of hyaluronic acid and forms to prevent the narrowing of the vascular walls |
| 02/08/2005 | US6852522 Methods and interferon deficient substrates for the propagation of viruses |
| 02/08/2005 | US6852520 DSP-2 dual-specificity phosphatase |
| 02/08/2005 | US6852518 Glycosyl sulfotransferases GST-4α, GST-4β, and GST-6 |
| 02/08/2005 | US6852343 Antiadipose topical treatment composition based on garlic bulbs extracts, and cosmetic and therapeutic uses |
| 02/08/2005 | US6852333 Agents and methods for promoting production gains in animals |
| 02/08/2005 | US6852320 T cell inhibitory receptor compositions and uses thereof |
| 02/06/2005 | CA2476801A1 Method and apparatus for the treatment of obesity |
| 02/03/2005 | WO2005010025A2 Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
| 02/03/2005 | WO2005009957A1 Tyrosine kinase inhibitors |
| 02/03/2005 | WO2005009475A1 Medicinal preparation containing component originating in bacteruim belonging to the genus clostridium |
| 02/03/2005 | WO2005009472A2 Dispersible pharmaceutical composition for treatment of mastitis and otic disorders |
| 02/03/2005 | WO2005009470A1 Remedy for cardiac failure comprising ask1 inhibitor as the active ingredient and method of screening the same |
| 02/03/2005 | WO2005009469A1 Novel drug for regulating blood sugar and method of screening the same |
| 02/03/2005 | WO2005009468A1 Remedy for cartilage-related diseases |
| 02/03/2005 | WO2005009446A1 Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome |
| 02/03/2005 | WO2005009444A1 Medicinal compositions |
| 02/03/2005 | WO2005009438A1 Nicotinamide compounds useful as pde4 inhibitors |
| 02/03/2005 | WO2005009434A2 Compounds and methods for inducing apoptosis in cancer cells |
| 02/03/2005 | WO2005009431A1 Methods for treating inflammation and inflammation-associated diseases with a statin and ether |
| 02/03/2005 | WO2005009412A1 Oral compositions for treatment of diseases |
| 02/03/2005 | WO2005009382A2 Antiglucocorticoid therapy for the prevention of neurological damage in premature infants |
| 02/03/2005 | WO2005009352A2 Antimicrobial compositons containing synergistic combinations of quaternary ammonium compounds and essential oils and/or constituents thereof |
| 02/03/2005 | WO2005009342A2 Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith |
| 02/03/2005 | WO2005009338A2 Method of inhibiting atf/creb and cancer cell growth and pharmaceutical compositions for same |
| 02/03/2005 | WO2005009336A2 Antibacterial methods and compositions |
| 02/03/2005 | WO2005009334A2 Reversible inhibitors of s-adenosyl-l-homocysteine hydrolase and uses thereof |
| 02/03/2005 | WO2005009143A2 Novel fluorinated food products and the use thereof for harmonious osseous development |
| 02/03/2005 | WO2004078122A3 Invisible patch for active agnet controlled delivery |
| 02/03/2005 | WO2004048431A3 Polyphosphazene immunocstimulants |
| 02/03/2005 | WO2004002416A3 Methods and materials for treating human papillomavirus infections |
| 02/03/2005 | WO2003106450A8 Phenylaminopyrimidines and their use as rho-kinase inhibitors |
| 02/03/2005 | WO2003094859A3 Epha2 monoclonal antibodies and methods of use thereof |
| 02/03/2005 | WO2003081250A8 Novel compositions and methods in cancer associated with altered expression of prlr |
| 02/03/2005 | WO2003064606A3 Human monoclonal antibodies to prostate specific membrane antigen (psma) |
| 02/03/2005 | WO2003063779A3 Selective analgesic agents |
| 02/03/2005 | WO2003062390A3 Compositions and methods for the modulation of sphingolipid metabolism and/or signaling |
| 02/03/2005 | WO2003040317A8 Lung cancer therapeutics and diagnostics |
| 02/03/2005 | WO2003039342A3 Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145 |
| 02/03/2005 | US20050027115 Cationic lipid-mediated enhancement of nucleic acid immunization of cats |
| 02/03/2005 | US20050027114 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 02/03/2005 | US20050027103 Matrix protein for use diagnosis, treatment, and prevention of viral infections, cell proliferative and neurological disorders |
| 02/03/2005 | US20050027019 Aqueous 2,6-diisopropylphenol pharmaceutical compositions |
| 02/03/2005 | US20050027007 Allylamides useful in the treatment of alzheimer's disease |
| 02/03/2005 | US20050027000 Use of apogossypol derivatives to treat cancer; drug screening for Bcl-2 protein inhibitors |
| 02/03/2005 | US20050026996 A taxane such as paclitaxel or docetaxel joined by a hydrolyzable bond to one or more oligomers having a polyethylene glycol moiety; amphiphilic drug conjugate with improved water solubility without drastic increase in molecular weight |
| 02/03/2005 | US20050026992 Treatment and prevention of cardiovascular events |
| 02/03/2005 | US20050026986 Use of central cannabinoid receptor antagonists for the preparation of drugs |
| 02/03/2005 | US20050026979 Methods for treating inflammation and inflammation-associated diseases with a statin and ether |